English
Back
Download
Log in to access Online Inquiry
Back to the Top

Pfizer on track to post best monthly gain in nearly three decades

Despite a threat to vaccine-driven immunity with the recent emergence of the new COVID-19 variant Omicron, $Pfizer (PFE.US)$ is on course to record its best monthly gain since Dec. 1991.
Over the past 12 months, the shares of the New York-based pharma giant has climbed ~40.8% well outperforming the broader index, as indicated in the graph below. Driven by the sales of the vaccine it co-developed with $BioNTech (BNTX.US)$ , its revenue has more than doubled over the past year.
Pfizer’s performance contrasts with rival vaccine maker $Moderna (MRNA.US)$ whose CEO has warned that the COVID-19 vaccines could lose efficacy against Omicron, classified by the World Health Organization (WHO) as a global variant of concern.
However, Pfizer targets both preventative and therapeutic aspects of the disease with its vaccine and the experimental COVID-19 pill Paxlovid, for which the company has already sought U.S. regulatory authorization.
Pfizer on track to post best monthly gain in nearly three decades
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
1
2
29
+0
13
Translate
Report
70K Views
Comment
Sign in to post a comment

View more comments...

254
Followers
14
Following
327
Visitors
Follow
Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.